What is RapidClaims?
Autonomous AI agents for medical coding, denials, and revenue-cycle workflows.
- Category
- Revenue cycle AI
- Headquarters
- New York, NY
- Founded
- 2023
- Employees
- 21-40 reported
- Total funding
- $11M
- Status
- Private; Series A
What is RapidClaims?
RapidClaims is a revenue cycle ai company. RapidClaims markets autonomous AI agents that code charts, improve documentation, prevent denials, and recover revenue across mid-revenue-cycle workflows.
RapidClaims is a revenue cycle ai company with headquarters listed as New York, NY. Autonomous AI agents for medical coding, denials, and revenue-cycle workflows. RapidClaims markets autonomous AI agents that code charts, improve documentation, prevent denials, and recover revenue across mid-revenue-cycle workflows.
The company is currently best read as Private; Series A. Public sources show $11M in funding and Not publicly disclosed; where revenue, ARR, margin, or exact customer counts are not published, this profile avoids inventing them and uses funding, footprint, product coverage, and public scale signals instead.
For sellers, the account matters because buying centers span clinical operations, compliance, product, data, security, finance, and growth. The strongest pitch is tied to measurable access, quality, cost, workflow, or workforce outcomes rather than generic software adoption.
What does RapidClaims offer?
RapidClaims offers Autonomous coding agents, Clinical documentation improvement, Denial prevention, Revenue recovery, and related workflows.
- Autonomous coding agents· Core product
- Clinical documentation improvement· Core product
- Denial prevention· Care workflow
- Revenue recovery· Care workflow
- EHR integrations· Expansion
- RCM analytics· Expansion
How does RapidClaims make money?
RapidClaims sells enterprise SaaS and workflow automation to healthcare providers, RCM teams, and health systems looking to improve coding, denial prevention, and reimbursement.
RapidClaims sells enterprise SaaS and workflow automation to healthcare providers, RCM teams, and health systems looking to improve coding, denial prevention, and reimbursement.
Pricing is not public; buyer economics are ROI-driven enterprise contracts based on chart volume, workflow scope, implementation, and recovered revenue. Growth is driven by adoption in revenue cycle ai, expansion into larger accounts or additional geographies, and proof that the product improves outcomes, cost, capacity, or experience.
Because the company is private, this profile does not invent revenue, gross margin, or unit economics. Sellers should qualify budget owner, reimbursement model, procurement path, compliance requirements, and integration effort early.
Who leads RapidClaims?
RapidClaims is led by Dushyant Mishra, Jot Sarup Singh, Abhinay Vyas, Moh Ibtesaam.
- Dushyant MishraCo-founder & CEOFounderFormer Abbott operator focused on revenue-cycle automation.
- Jot Sarup SinghCo-founder & CPTOFounderLeads product and technology for healthcare LLM workflows.
- Abhinay VyasCo-founder & CDOFounderLeads data science and AI adoption.
- Moh IbtesaamHead of Growth & MarketingCurrent leaderLeads GTM growth in U.S. healthcare.
How do you contact RapidClaims's leadership?
RapidClaims does not publish verified personal executive emails in the reviewed public sources. Use official company contact, demo, support, partnerships, or careers routes rather than guessed personal emails.
Personal executive email format not verified; use official company routingHow much funding has RapidClaims raised?
RapidClaims has $11M in public or reported funding; latest disclosed round: Apr 2025 Series A ($8M).
RapidClaims's disclosed funding history is: 2023 Seed: $3M, valuation not disclosed, led/backed by Together Fund; Apr 2025 Series A: $8M, valuation not disclosed, led/backed by Accel.
The latest public valuation/status used here is Not publicly disclosed. If a valuation is not disclosed, this profile treats the company as private with no public priced mark rather than inferring a number from round size.
Seller signal: funding indicates capacity to invest, but healthcare buyers still require security, compliance, implementation proof, and outcomes evidence. New capital is most likely to support market expansion, hiring, product development, clinical operations, data, AI, and partnerships.
How did RapidClaims get here?
RapidClaims reached its current stage through founding, product expansion, and major financing milestones.
- 2023Founded and seedRapidClaims launches with Together Fund seed backing.
- 2024Market launchRapidClaims begins marketing AI-native RCM workflows.
- Apr 2025$11M total disclosedAccel leads $8M Series A and previously undisclosed $3M seed is announced.
- 2025Frost & Sullivan recognitionRapidClaims markets 2025 Technology Innovation Leader recognition.
- 2026Autonomous-agent expansionRapidClaims positions around coding, denials, and revenue recovery.
Who are RapidClaims's competitors?
RapidClaims competes with adjacent healthcare providers, software platforms, marketplaces, and care-navigation companies.
RapidClaims — frequently asked questions
